SGBI news today huge $$$ revenue coming with minimum purchase order from Asia
Sangui BioTech: SastoMed Enters into Sales Agreements for Southeast Asia, Poland and Russia
Last update: 02/11/2016 6:00:01 am
-- Firm purchase commitments agreed
WITTEN, Germany--(BUSINESS WIRE)--November 02, 2016--
SastoMed GmbH, to which Sangui BioTech GmbH has licensed the worldwide distribution rights for the wound spray Granulox, concluded a comprehensive licensing and sales agreement for eight Southeast Asian States with Zuellig Pharma, Singapure (www.zuelligpharma.com) one of the world's leading service providers of the pharmaceuticals. Zuellig Pharma is responsible for market launch and distribution of Granulox in the territories of Hong Kong, Singapore, Thailand, Malaysia, Taiwan, Vietnam, Indonesia and the Philippines. In addition to the complete processing and financing of admission in the individual territories, Zuellig Pharma has committed itself to the purchase of significant quantities of Granulox within the next five years. Furthermore, two high -- performance distribution partners could be bound: Hexanova Sp.z.o.o. for Poland (www.hexanova.pl) and MDP Group for Russia (www.mdp-group.net). In both cases, minimum purchase commitments were also been agreed upon.
"With these agreements, we have succeeded in pushing forward into new dimensions. Inside the newly acquired sales areas, more than half a billion people live. We have now reached an important milestone on our path to global expansion. In addition to the quantitative dimension, the qualitative contract value of the agreements was also increased. In the past five years, Granulox has proven in field that it keeps what it promises on paper. When granting new territories, we now benefit from the appreciation Granulox has now gained. For instance, Zuellig Pharma for Southeast Asia and the MDP Group for Russia, two veritable global players with a corresponding sales force and financial strength, could be obtained for Granulox. Both partners have committed themselves to realize the necessary regulatory approvals and subsequent market launch of Granulox in the respective territories. Guaranteed purchase commitments were agreed with both partners. The annual minimum purchase quantities fixed within the next five-year period up to 2021 are based on the time-staggered progress of the product launches expected by Zuellig Pharma and MDP Group. Starting with the approval of Granulox, followed by the starts of the marketing campaigns and Granulox's positive sales development, specific verifiable milestones were established together with our partners for the individual territories. The cumulative purchase commitments for quantities over the next five years are well in the middle six-digit range. On the one hand, this minimum order gives us further planning certainty and ensures that we achieve our ambitious goals. On the other hand, this fact underscores the strong confidence our partners have in the future success of the cooperation with SastoMed ", explains Michael Sander, CEO of Sastomed GmbH.
"We congratulate SastoMed on these breakthroughs. After the inclusion of Granulox in the Drug Tariff of the British NHS at the beginning of October 2016, SastoMed herewith has reached further trend-setting successes. Sangui as licensors for Granulox will definitively benefit from these success. In this regard, the year 2016 can be described as very successful ", says Thomas Striepe, President and CEO of Sangui BioTech International Inc.
Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.
News 
Market Data 
Discover 
